Dr. Christine A. Peschken from the University of Manitoba in Winnipeg presented data on lupus disease in a Canadian cohort of patients, during the 70th Annual Meeting of The Canadian Rheumatology Association (CRA) in Quebec, Canada. The poster was entitled “Residual Lupus Disease Activity in a…
Recent findings might help ease concerns for women suffering with lupus and interested in having a child. New research concluded that most women diagnosed with lupus and whose disease is not very active can go through a safe pregnancy. The results were published in the Annals of Internal Medicine. It has been suggested that women with…
Kadmon Corporation, LLC, a biopharmaceutical company focused on autoimmune, fibrotic, metabolic diseases and the oncology field, recently announced promising preclinical data on its KD025 drug in the treatment of systemic lupus erythematosus (SLE). The data was presented in May 2015 at the American Association of Immunologists (AAI) Annual…
Susan Manzi, Chair of the Department of Medicine at Allegheny Health Network, was recently presented with the Lupus Foundation of America’s (LFA) National Advocacy Leadership Award. The LFA awarded those with exquisite and distinguished researched who lead and support biomedical innovation to accelerate the development of novel treatments for illnesses such as lupus.
Anthera Pharmaceuticals recently announced it has completed the enrolment of patients for its CHABLIS-SC1 Phase 3 study evaluating blisibimod as a lupus treatment. The company expects to have final data from the trial by the end of 2016. “Reaching our enrollment target for CHABLIS-SC1 ahead of schedule is an important accomplishment,” said in…
An international team led by researchers at the University of Bergen in Norway and the Weizmann Institute of Science in Israel recently published in the journal Immunity their finding that mutations in a gene known as autoimmune regulator (AIRE) are linked to different autoimmune phenotypes.
An international team of researchers recently published in the journal Nature Materials new findings on the activation of the body’s immune response in autoimmune disorders like systemic lupus erythematosus (SLE) and psoriasis. The study is entitled “Liquid-crystalline ordering of antimicrobial peptide–DNA complexes controls TLR9…
During the recent European League Against Rheumatism Annual Congress (EULAR 2015) that took place June 11-13 in Rome, Italy, new clinical recommendations for patients with systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS) who are trying to conceive or are currently pregnant were presented by the league. These new recommendations…
A study led by researchers at Ludwig Maximilians University Munich in Germany revealed a promising new biomarker linked to the lifespan control of important antibody-producing cells and relevant for autoimmune diseases like systemic lupus erythematosus (SLE). The study was recently published in the journal Nature Communications…
Systemic lupus erythematosus (SLE) treatments try to efficiently manage the disease while being safe and carrying a low rate of adverse events. Different strategies are currently used to control disease activity and prevent organ damage. To further understand if SLE is being adequately treated, a team of researchers lead by Dr. Christine Peschken looked at disease…